Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study

被引:45
作者
Behera, Priyamadhaba [1 ]
Patro, Binod Kumar [1 ]
Singh, Arvind Kumar [1 ]
Chandanshive, Pradnya Dilip [1 ]
Ravikumar, S. R. [1 ]
Pradhan, Somen Kumar [1 ]
Pentapati, Siva Santosh Kumar [1 ]
Batmanabane, Gitanjali [2 ]
Mohapatra, Prasanta Raghab [3 ]
Padhy, Biswa Mohan [4 ]
Bal, Shakti Kumar [3 ]
Singh, Sudipta Ranjan [5 ]
Mohanty, Rashmi Ranjan [6 ]
机构
[1] All India Inst Med Sci Bhubaneswar, Dept Community Med & Family Med, Bhubaneswar, India
[2] All India Inst Med Sci Bhubaneswar, Bhubaneswar, India
[3] All India Inst Med Sci Bhubaneswar, Dept Pulm Med & Crit Care, Bhubaneswar, India
[4] All India Inst Med Sci Bhubaneswar, Dept Pharmacol, Bhubaneswar, India
[5] All India Inst Med Sci Bhubaneswar, Dept Forens Med & Toxicol, Bhubaneswar, India
[6] All India Inst Med Sci Bhubaneswar, Dept Gen Med, Bhubaneswar, India
基金
英国科研创新办公室;
关键词
COVID-19;
D O I
10.1371/journal.pone.0247163
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Ivermectin is one among several potential drugs explored for its therapeutic and preventive role in SARS-CoV-2 infection. The study was aimed to explore the association between ivermectin prophylaxis and the development of SARS-CoV-2 infection among healthcare workers. Methods A hospital-based matched case-control study was conducted among healthcare workers of AIIMS Bhubaneswar, India, from September to October 2020. Profession, gender, age and date of diagnosis were matched for 186 case-control pairs. Cases and controls were healthcare workers who tested positive and negative, respectively, for COVID-19 by RT-PCR. Exposure was defined as the intake of ivermectin and/or hydroxychloroquine and/or vitamin-C and/or other prophylaxis for COVID-19. Data collection and entry was done in Epicollect5, and analysis was performed using STATA version 13. Conditional logistic regression models were used to describe the associated factors for SARS-CoV-2 infection. Results Ivermectin prophylaxis was taken by 76 controls and 41 cases. Two-dose ivermectin prophylaxis (AOR 0.27, 95% CI, 0.15-0.51) was associated with a 73% reduction of SARS-CoV-2 infection among healthcare workers for the following month. Those involved in physical activity (AOR 3.06 95% CI, 1.18-7.93) for more than an hour/day were more likely to contract SARS-CoV-2 infection. Type of household, COVID duty, single-dose ivermectin prophylaxis, vitamin-C prophylaxis and hydroxychloroquine prophylaxis were not associated with SARS-CoV-2 infection. Conclusion Two-dose ivermectin prophylaxis at a dose of 300 mu g/kg with a gap of 72 hours was associated with a 73% reduction of SARS-CoV-2 infection among healthcare workers for the following month. Chemoprophylaxis has relevance in the containment of pandemic.
引用
收藏
页数:12
相关论文
共 28 条
[1]   Protective measures for COVID-19 for healthcare providers and laboratory personnel [J].
Agalar, Canan ;
Ozturk Engin, Derya .
TURKISH JOURNAL OF MEDICAL SCIENCES, 2020, 50 :578-584
[2]  
[Anonymous], 2020, HLTH WORKERS EXPOSUR
[3]  
[Anonymous], 2020, Revised advisory on the use of Hydroxychloroquine (HCQ) as prophylaxis for COVID-19 infection
[4]  
[Anonymous], 2020, Associated General Contractors of America
[5]  
[Anonymous], 2020, PHASE 3 TRIAL PROMOT
[6]  
[Anonymous], 2021, WHO CORONAVIRUS DIS
[7]  
[Anonymous], 2020, Coronavirus disease (COVID-19) advice for the public: mythbusters
[8]   A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 [J].
Boulware, David R. ;
Pullen, Matthew F. ;
Bangdiwala, Ananta S. ;
Pastick, Katelyn A. ;
Lofgren, Sarah M. ;
Okafor, Elizabeth C. ;
Skipper, Caleb P. ;
Nascene, Alanna A. ;
Nicol, Melanie R. ;
Abassi, Mahsa ;
Engen, Nicole W. ;
Cheng, Matthew P. ;
LaBar, Derek ;
Lother, Sylvain A. ;
MacKenzie, Lauren J. ;
Drobot, Glen ;
Marten, Nicole ;
Zarychanski, Ryan ;
Kelly, Lauren E. ;
Schwartz, Ilan S. ;
McDonald, Emily G. ;
Rajasingham, Radha ;
Lee, Todd C. ;
Hullsiek, Kathy H. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (06) :517-525
[9]   The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro [J].
Caly, Leon ;
Druce, Julian D. ;
Catton, Mike G. ;
Jans, David A. ;
Wagstaff, Kylie M. .
ANTIVIRAL RESEARCH, 2020, 178
[10]  
Cheng Richard Z, 2020, Glob Adv Health Med, V9, p2164956120934768, DOI 10.1177/2164956120934768